ArticleClinical case reports2026
Successful Treatment of Pigmented Purpuric Dermatoses With Abrocitinib: A Case Report.
Article in Clinical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pigmented Purpuric Dermatoses (PPD) are chronic conditions often resistant to standard treatments, creating a need for new therapies, particularly for those suffering from severe itching. This report details a patient with a year of refractory lower-extremity PPD who failed multiple oral and topical treatments. The patient was then successfully treated with oral abrocitinib (100 mg daily). Significant relief from pruritus occurred within 2 weeks, and substantial improvement in the skin lesions followed by the sixth week. After 3 months of treatment, lesions resolved to simple brown patches, with no recurrence seen during a four-month follow-up and no significant side effects noted. These results suggest that the JAK1 inhibitor abrocitinib possesses potential as a safe and highly effective treatment option for refractory PPD, warranting further clinical study.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.